QMC HealthID Provides COVID Testing Support For Victoires De La Musique Awards Ceremony
Quantum Materials Corp announced the deployment of its QMC HealthID™ software platform for voluntary COVID testing at the Les Victoires de la Musique awards in Paris. Collaborating with Innova Medical Group, the platform facilitated real-time verification and outcome notifications for participants undergoing rapid COVID-19 testing. The effort showcased a commitment to ensuring safe events and aligns with QMC's mission to support public health initiatives. The company emphasizes its role in overcoming global health challenges through innovation and technology.
- Deployment of QMC HealthID™ at a high-profile event demonstrates practical application and market value.
- Collaboration with Innova Medical Group enhances credibility and reach in COVID-19 testing solutions.
- No financial metrics or results were provided, leaving uncertainty about revenue impact from this initiative.
QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, announced that it had deployed its QMC HealthID™ software platform to assist with voluntary COVID testing at Les Victoires de la Musique music industry awards ceremony held February 12th in Paris, France.
Held yearly since 1985, Les Victoires de la Musique is an annual French award ceremony delivered by the French Ministry of Culture that recognizes outstanding achievement in the music industry and the best musical artists of the year.
In conjunction with test manufacturer Innova Medical Group, a COVID-19 screening area was set up to voluntarily administer the Innova SARS-CoV-2 Antigen Rapid Qualitative Test. During the pre-event screening process, the QMC HealthID™ mobile application platform enabled medical staff to verify participants, assess their test result outcome, and then notify the participants of their test outcomes.
“By supporting this major national cultural event, QMC HealthID and Innova allowed the media and the participants to experience a simple and viable solution to make the awards ceremony safer against COVID-19,” said Xavier Guerin, President of EMEA of Innova Medical Group.
The production of the Victoires De La Musique Ceremony requires approximately 400 technicians and journalists in addition to the musicians themselves. QMC and Innova coordinated on pre-event COVID-19 testing to demonstrate that the event production company was taking appropriate precautions to protect the health of the musicians as well as journalists and all event production staff.
“QMC was honored to play a part in the COVID prevention plans for the Les Victoires de la Musique awards ceremony,” said Stephen B. Squires, CEO of Quantum Materials Corp. “Helping make the awards ceremony safer to attend in person is
About Quantum Materials Corp
At Quantum Materials our scientists and engineers believe in the power of innovation to make life better and solve critical problems facing our world. Whether its applied research into quantum materials, the development of advanced digital platforms, or creating new tools for personal health, we find our inspiration in discovering new solutions to build a better future for all. Quantum Materials is pioneering unique solutions in the area of quantum dot fabrication, quantum tagging, digital trust systems, and most recently, in the development of QMC HealthID™. Our team comprises experts in the areas of quantum materials, nanotechnology, health diagnostics, therapeutic health, digital platforms, advanced logistics, and anti-counterfeiting. As a company, we believe in collaboration. We find that innovation begins with the spark of a new insight that is rigorously pursued in a collegial and interdisciplinary environment. Bringing breakthrough ideas to life and forging new solutions inspires our work. For more information, visit Quantum Materials Corp at www.quantummaterialscorp.com
About QMC HealthID Inc.
QMC HealthID Inc., a wholly owned subsidiary of Quantum Materials Corp. (OTC Bulletin Board: QTMM), leverages its QMC technologies to address global health challenges spurred by current and future pandemics. The QMC HealthID management platform and mobile app authenticates the process of infectious disease testing and gives the individual control over the data they share and their personal health status. Virtually any current COVID-19 point of care or laboratory-based diagnostic test, including Innova Medical Group’s, SARS-CoV-2 Antigen Rapid Qualitative Test, can be implemented in the QMC HealthID™ testing and reporting solution. These tests along with the mobile app are designed to test for COVID-19, with benefit towards helping people get safely and securely back to work, school, travel, events and living. For more information, please visit www.qmchealthid.com.
QMC HealthID™, Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although QMC HealthID’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of QMC HealthID™, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, QMC HealthID’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly, and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. Other than as required by applicable law, QMC HealthID™ does not undertake any obligation to update or revise any forward-looking information or statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005626/en/
FAQ
What is QMC HealthID's role in COVID testing at Les Victoires de la Musique?
When did the Les Victoires de la Musique ceremony take place?
What company is behind the QMC HealthID platform?
How does QMC HealthID enhance COVID testing?
Who partnered with QMC HealthID for the COVID testing?
